Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Voyager Therapeutics, Inc. (VYGR)

Voyager Therapeutics names COO Robin Swartz president; CEO succession planned after 2027 data

Neutral Impact 4 of 5 leadership Written later

Voyager Therapeutics said its board appointed Chief Business Officer and Chief Operating Officer Robin Swartz as President, effective immediately, and expects her to succeed CEO Alfred Sandrock after initial acute safety data from the VY1706 Alzheimer's trial, anticipated in the first quarter of 2027. Dr. Sandrock is expected to remain on the board, and Ms. Swartz's new employment agreement sets her base salary at $625,000 with severance protections that include acceleration of equity vesting after a sale event.

Key points

  • Robin Swartz appointed President effective October 20, 2026; she is also expected to succeed Alfred Sandrock as CEO after initial VY1706 safety data, anticipated in Q1 2027
  • Annualized base salary of $625,000 with a target annual cash bonus of 50% of base salary
  • Grants effective November 1, 2026: option to buy 318,500 shares and restricted stock units covering 68,250 shares
  • Severance if terminated without cause or for good reason; full equity acceleration if within 12 months after a sale event

The filing

CompanyVoyager Therapeutics, Inc. (VYGR)
Form8-K, current report
Filed with the SECOct 21, 2026, 8:07 AM ET
Accession number0001193125-26-427224

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.